Related Experiment Video

Updated: Jul 2, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

PMS777, a new cholinesterase inhibitor with anti-platelet activated factor activity, regulates amyloid precursor

Hong-Qi Yang1, Zhi-Kun Sun, Yan-Xin Zhao

  • 1Department of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.

Neurochemical Research
|September 2, 2008
PubMed

Insights

PMS777, a novel drug, reduces beta-amyloid (Abeta) production by modulating amyloid precursor protein (APP) processing. This suggests PMS777 may offer therapeutic potential for Alzheimer's disease (AD).

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder marked by memory and cognitive decline.
  • The beta-amyloid (Abeta) cascade is a key factor in AD pathophysiology.
  • Modulating amyloid precursor protein (APP) metabolism is a potential therapeutic strategy for AD.

Purpose of the Study:

  • To investigate the effects of PMS777, a cholinesterase inhibitor with anti-platelet activated factor activity, on APP processing.
  • To determine if PMS777 influences the generation of Abeta, a critical component in AD.

Main Methods:

  • Experiments were conducted using SH-SY5Y(APP695) and PC12 cell lines.
  • Cells were treated with PMS777, and the secretion of sAPPalpha and Abeta42 was measured.
  • Receptor antagonists (scopolamine and alpha-bungarotoxin) were used to explore the mechanism of action.

Main Results:

  • PMS777 significantly decreased the secretion of sAPPalpha in both cell lines without affecting holoAPP synthesis.
  • PMS777 treatment reduced the release of Abeta42 in SH-SY5Y(APP695) cells.
  • Scopolamine pretreatment antagonized the effect of PMS777 on sAPPalpha secretion, while alpha-bungarotoxin did not.

Conclusions:

  • PMS777 demonstrates the ability to modulate APP processing in vitro.
  • The drug's capacity to decrease Abeta generation indicates its potential therapeutic value for Alzheimer's disease.
  • The mechanism appears to involve M-receptor pathways.

More Related Videos

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...